Audiomedica.com
Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 11:00:00
- Mas informaciones
Informações:
Sinopsis
COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced non-squamous non-small-cell lung cancer (NSCLC) and good performance status significantly improved objective response rate (ORR) and progression-free …161123-ajo-esmo-corey-langer-production-master